Norman Selby - Infinity Pharmaceuticals Lead Outside Independent Director
| INFIDelisted Stock | USD 0.04 0.03 42.86% |
Director
Mr. Norman C. Selby serves as Lead Outside Independent Director of Infinity Pharmaceuticals Inc. Mr. Selby has served as a Senior Advisor of Perseus, L.L.C., a merchant bank and private equity fund management company, since August 2005 and as executive chairman of Real Endpoints, LLC, a healthcare information company focused on the changing landscape of reimbursement, since October 2010. Previously, Mr. Selby was President and CEO of TransForm Pharmaceuticals, Inc., a privately held specialty pharmaceutical company that was acquired by Johnson Johnson in April 2005. Prior to TransForm Pharmaceuticals, Mr. Selby was an Executive Vice President at CitigroupCiticorp from 19972000. Mr. Selby spent the bulk of his career at McKinsey Company where he was Director in the firms New York office. He held several leadership roles at McKinsey, including head of the firms Global Pharmaceuticals and Medical Products Practice. From 19871989, Mr. Selby took a leave of absence from McKinsey to serve as Chief Operating Officer of the New York Blood Center, the largest community blood organization in the country, where he led its financial and operational turnaround. Mr. Selby is currently a member of the board of directors of the following privately held companies Ascenta Therapeutics, Inc., a biopharmaceutical company Physicians Interactive Holdings, Inc., a provider of online and mobile clinical resources and solutions Real Endpoints, LLC, a healthcare information company Merz GmbH, a specialty pharmaceutical company and Metamark Genetics, a life science diagnostics company since 2013.
| Age | 61 |
| Tenure | 11 years |
| Professional Marks | MBA |
| Phone | 617 453 1000 |
| Web | https://www.infi.com |
Infinity Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.607) % which means that it has lost $0.607 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (35.2135) %, meaning that it created substantial loss on money invested by shareholders. Infinity Pharmaceuticals' management efficiency ratios could be used to measure how well Infinity Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 917 K in liabilities with Debt to Equity (D/E) ratio of 0.13, which may suggest the company is not taking enough advantage from borrowing. Infinity Pharmaceuticals has a current ratio of 4.08, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Infinity Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Infinity Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Infinity Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Infinity to invest in growth at high rates of return. When we think about Infinity Pharmaceuticals' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Jennifer Lee | Aditxt Inc | N/A | |
| Theodore Wang | TRACON Pharmaceuticals | 50 | |
| Vimal Vallabh | Instil Bio | N/A | |
| Elaine Jones | CytomX Therapeutics | 60 | |
| William LaRue | TRACON Pharmaceuticals | 66 | |
| Susan Mahony | Assembly Biosciences | 52 | |
| Timothy Wollaeger | Chimerix | 68 | |
| James Meyers | CytomX Therapeutics | 54 | |
| Patrick Machado | Chimerix | 54 | |
| Clarence Machado | Chimerix | 51 | |
| John Rickard | Instil Bio | N/A | |
| Anthony Altig | Assembly Biosciences | 61 | |
| Aloke Banerjee | Instil Bio | 61 | |
| David Jakeman | Chimerix | 41 | |
| George Rohlinger | Instil Bio | N/A | |
| Veena Hingarh | Instil Bio | N/A | |
| Tridibesh Mukherjee | Instil Bio | 74 | |
| Stephen Worland | TRACON Pharmaceuticals | 59 | |
| Ronald Renaud | Chimerix | 48 | |
| Myron Holubiak | Assembly Biosciences | 70 | |
| Alfred Scheidegger | TRACON Pharmaceuticals | 58 | |
Management Performance
| Return On Equity | -35.21 | |||
| Return On Asset | -0.61 |
Infinity Pharmaceuticals Leadership Team
Elected by the shareholders, the Infinity Pharmaceuticals' board of directors comprises two types of representatives: Infinity Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Infinity. The board's role is to monitor Infinity Pharmaceuticals' management team and ensure that shareholders' interests are well served. Infinity Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Infinity Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Joseph Pearlberg, Vice President - Clinical Development | ||
| Melissa Hackel, Vice President - Finance | ||
| William Bertrand, Executive Vice President General Counsel | ||
| Vito Palombella, Chief Scientific Officer and Executive VP | ||
| Jeffrey Berkowitz, Independent Director | ||
| Seth JD, Chief VP | ||
| Lawrence Bloch, CFO, Executive Vice President Chief Business Officer | ||
| Norman Selby, Lead Outside Independent Director | ||
| Jose Baselga, Independent Director | ||
| Samuel Agresta, Chief Medical Officer | ||
| Michael Venuti, Independent Director | ||
| Stephane Peluso, Chief Officer | ||
| MD Ilaria, Chief Officer | ||
| Jayne Kauffman, Sr Coordinator | ||
| Michael Kauffman, Independent Director | ||
| Eric Lander, Independent Director | ||
| David Beier, Independent Director | ||
| Julian Adams, President of RandD | ||
| Anthony Evnin, Independent Director | ||
| Gwendolyn Fyfe, Independent Director | ||
| Sujay Kango, Executive Vice President Chief Commercial Officer | ||
| Ian Smith, Independent Director | ||
| Adelene Perkins, Chairman of The Board, CEO and Pres | ||
| MD JD, Pres Treasurer |
Infinity Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Infinity Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -35.21 | |||
| Return On Asset | -0.61 | |||
| Operating Margin | (15.70) % | |||
| Current Valuation | (9.46 M) | |||
| Shares Outstanding | 90.76 M | |||
| Shares Owned By Insiders | 2.36 % | |||
| Shares Owned By Institutions | 23.48 % | |||
| Number Of Shares Shorted | 2.21 M | |||
| Price To Earning | (1.63) X | |||
| Price To Book | 8.03 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Infinity Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Infinity Pharmaceuticals' short interest history, or implied volatility extrapolated from Infinity Pharmaceuticals options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in census. Note that the Infinity Pharmaceuticals information on this page should be used as a complementary analysis to other Infinity Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Other Consideration for investing in Infinity Stock
If you are still planning to invest in Infinity Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Infinity Pharmaceuticals' history and understand the potential risks before investing.
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators |